Cinnamyl-3,4-dihydroxy-α-cyanocinnamate and nordihydroguaiaretic acid inhibit human Kv1.5 currents independently of lipoxygenase

European Journal of Pharmacology

Volumn 600, Issue 1-3, 2008, Pages 18-25

  Gong, Ying Zi ^a,b   Ding, Wei Guang ^a   Wu, Jie ^c   Tsuji, Keiko ^a   Horie, Minoru ^a   Matsuura, Hiroshi ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b HARBIN UNIVERSITY   (China)

^c XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

CDC; IKur; Kv1.5; Lipoxygenase; NDGA; Open channel block; Site directed mutagenesis

Indexed keywords

CINNAMIC ACID DERIVATIVE; CINNAMYL 3,4 DIHYDROXY ALPHA CYANOCINNAMATE; GOSSYPOL; LIPOXYGENASE; NORDIHYDROGUAIARETIC ACID; POTASSIUM CHANNEL KV1.5; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; IC 50; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS;

ANIMALS; BINDING SITES; CAFFEIC ACIDS; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; GOSSYPOL; HUMANS; INHIBITORY CONCENTRATION 50; KV1.5 POTASSIUM CHANNEL; LIPOXYGENASE INHIBITORS; MUTAGENESIS, SITE-DIRECTED; MUTATION; NORDIHYDROGUAIARETIC ACID; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; TIME FACTORS;

EID: 55949115257     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.10.010     Document Type: Article

References (39)

1. Beetens J.R., Loots W., Somers Y., Coene M.C., and Clerck F.D.E. Ketoconazole inhibits the biosynthesis of leukotrienes in vitro and in vivo. Biochem. Pharmacol. 35 (1986) 883-891
2. Brendel J., and Peukert S. Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias. Curr. Med. Chem. Cardiovasc. Hematol. Agents 1 (2003) 273-287
3. Bril A. Recent advances in arrhythmia therapy: treatment and prevention of atrial fibrillation. Curr. Opin. Pharmacol. 2 (2002) 154-159
4. Caballero R., Moreno I., Gonzalez T., Valenzuela C., Tamargo J., and Delpon E. Putative binding sites for benzocaine on a human cardiac cloned channel (Kv1.5). Cardiovasc. Res. 56 (2002) 104-117
5. Cho H., Ueda M., Tamaoka M., Hamaguchi M., Aisaka K., Kiso Y., Inoue T., Ogino R., Tatsuoka T., Ishihara T., Noguchi T., Morita I., and Murota S. Novel caffeic acid derivatives: extremely potent inhibitors of 12-lipoxygenase. J. Med. Chem. 34 (1991) 1503-1505
6. + currents. J. Pharmacol. Exp. Ther. 304 (2003) 706-712
7. Choi B.H., Choi J.S., Jeong S.W., Hahn S.J., Yoon S.H., Jo Y.H., and Kim M.S. Direct block by bisindolylmaleimide of rat Kv1.5 expressed in Chinese hamster ovary cells. J. Pharmacol. Exp. Ther. 293 (2000) 634-640
8. Chugh S.S., Blackshear J.L., Shen W.K., Hammill S.C., and Gersh B.J. Epidemiology and natural history of atrial fibrillation: clinical implications. J. Am. Coll. Cardiol. 37 (2001) 371-378
9. Danthi S., Enyeart J.A., and Enyeart J.J. Caffeic acid esters activate TREK-1 potassium channels and inhibit depolarization-dependent secretion. Mol. Pharmacol. 65 (2004) 599-610
10. Decher N., Kumar P., Gonzalez T., Pirard B., and Sanguinetti M.C. Binding site of a novel Kv1.5 blocker: a foot in the door against atrial fibrillation. Mol. Pharmacol. 70 (2006) 1204-1211
11. + channels. J. Biol. Chem. 279 (2004) 394-400
12. + channel current. Circ. Res. 73 (1993) 210-216
13. CRAC in rat basophilic leukaemia cells. J. Phosiol. 539 (2002) 93-106
14. Hatton C.J., and Peers C. Multiple effects of nordihydroguaiaretic acid on ionic currents in rat isolated type I carotid body cells. Br. J. Pharmacol. 122 (1997) 923-929
15. Herrera D., Mamarbachi A., Simoes M., Parent L., Sauve R., Wang Z., and Nattel S. A single residue in the S6 transmembrane domain governs the differential flecainide sensitivity of voltage-gated potassium channels. Mol. Pharmacol. 68 (2005) 305-316
16. + channel (Kv1.5) by polyunsaturated fatty acids. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 1937-1944
17. Jager H., and Grissmer S. Regulation of a mammalian Shaker-related potassium channel, hKv1.5, by extracellular potassium and pH. FEBS. Lett. 488 (2001) 45-50
18. Knobloch K., Brendel J., Peukert S., Rosenstein B., Busch A.E., and Wirth K.J. Electrophysiological and antiarrhythmic effects of the novel I(Kur) channel blockers, S9947 and S20951, on left vs. right pig atrium in vivo in comparison with the I(Kr) blockers dofetilide, azimilide, d,l-sotalol and ibutilide. Naunyn. Schmiedebergs Arch. Pharmacol. 366 (2002) 482-487
19. 2+ currents independently of lipoxygenase inhibition. Mol. Pharmacol. 38 (1990) 524-530
20. Kyte J., and Doolittle R.F. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 157 (1982) 105-132
21. + channels and ultrarapidly activating delayed rectifier potassium current. J. Pharmaco.l Exp. Ther. 317 (2006) 1054-1063
22. + current in human ventricular myocytes. Circ. Res. 78 (1996) 689-696
23. + channel. Science 309 (2005) 897-903
24. + channels. Science 250 (1990) 276-279
25. Meves H. Modulation of ion channels by arachidonic acid. Prog. Neurobiol. 43 (1994) 175-186
26. Perchenet L., and Clement-Chomienne O. Characterization of mibefradil block of the human heart delayed rectifier hKv1.5. J. Pharmacol. Exp. Ther. 295 (2000) 771-778
27. Rezazadeh S., Claydon T.W., and Fedida D. KN-93 (2-[N-(2-hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine), a calcium/calmodulin-dependent protein kinase II inhibitor, is a direct extracellular blocker of voltage-gated potassium channels. J. Pharmaco.l Exp. Ther. 317 (2006) 292-299
28. Roden D.M. Pharmacogenetics and drug-induced arrhythmias. Cardiovasc. Res. 50 (2001) 224-231
29. + channel gene KCNA5. Clin. Pharmacol. Ther. 77 (2005) 138-144
30. Snyders D.J., and Yeola S.W. Determinants of antiarrhythmic drug action. Electrostatic and hydrophobic components of block of the human cardiac hKv1.5 channel. Circ. Res. 77 (1995) 575-583
31. Stump G.L., Wallace A.A., Regan C.P., and Lynch Jr. J.J. In vivo antiarrhythmic and cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide. J. Pharmacol. Exp. Ther. 315 (2005) 1362-1367
32. Trotter B.W., Nanda K.K., Kett N.R., Regan C.P., Lynch J.J., and Stump G.L. Design and synthesis of novel soquinoline-3-nitriles as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillation. J. Med. Chem. 49 (2006) 6954-6957
33. Valenzuela C., Delpón E., Franqueza L., Gay P., Pérez O., Tamargo J., and Snyders D.J. Class III antiarrhythmic effects of zatebradine. Time-, state-, use-, and voltage-dependent block of hKv1.5 channels. Circulation 94 (1996) 562-570
34. Varro A., Biliczki P., Iost N., Virag L., Hala O., Kovacs P., Matyus P., and Papp J.G. Theoretical possibilities for the development of novel antiarrhythmic drugs. Curr. Med. Chem. 11 (2004) 1-11
35. 2+ influx via T-type channels modulates PDGF-induced replication of mouse fibroblasts. Am. J. Physiol. 265 (1993) C1239-C1246
36. + current similar to Kv1.5 cloned channel currents. Circ. Res. 73 (1993) 1061-1076
37. + channel Kv1.5. Biophys. J. 79 (2000) 2416-2433
38. + current by nordihydroguaiaretic acid in porcine coronary arterial smooth muscle cells. J. Pharmacol. Exp. Ther. 291 (1999) 140-146
39. + channel. Role of S6 in antiarrhythmic drug binding. Circ. Res. 78 (1996) 1105-1114